October 30, 2020

The Niche

Knoepfler lab stem cell blog

Health News Review

2 min read

Stem cell studies continue to make big news with a mixed bag of trends, and some good stem cell news and others not so much. Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a big announcement. When that news came today it was discouraging in the form of its partner Teva choosing to end their relationship with Mesoblast on a stem cell heart disease trial. Mesoblast spun this as something good that they regained the rights from Teva, but investors …Read More

2 min read

Over at RetractionWatch, their team does a great job following retractions of science papers. Sadly, the number of published manuscript retractions gives them more than enough material to post several times a day. There’s another phenomenon going on that I think might warrant their increased attention: the possibly rising number of retractions or corrections of science press releases (PR). Gary Schwitzer, over at Health News Review, is reviewing science PRs, which is really interesting reading. I highly recommend that you check it out. While recent data …Read More